市場調査レポート

商品コード

1414711

脳卒中管理の世界市場：タイプ別、用途別：機会分析と産業予測（2022年～2032年）

Stroke Management Market By Type (Diagnostics, Therapeutics, Software), By Application (Ischemic Stroke, Haemorrhagic Stroke): Global Opportunity Analysis and Industry Forecast, 2022-2032

出版日: 2023年11月30日 | 発行: Allied Market Research

| ページ情報: 英文 230 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,820 904,777円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,540 1,016,708円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,870 1,534,390円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.46円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の脳卒中管理の市場規模は、2022年に361億米ドルに達し、2022年～2032年にCAGR7.4％で成長し、2032年には740億米ドルに達すると予測されています。

脳卒中は、血管の破裂や脳への血液供給の閉塞により、脳への血液供給が突然遮断されることで起こる病状です。その結果、脳組織への酸素が欠乏し、脳細胞が急速に死滅します。脳卒中には主に虚血性脳卒中、一過性脳虚血発作、出血性脳卒中の3種類があります。脳卒中の診断と治療に対する包括的なアプローチは、脳卒中管理と呼ばれています。脳卒中の診断には、磁気共鳴画像、頸動脈超音波、脳血管造影、血液検査などが含まれます。脳卒中は、組織プラスミノーゲン活性化薬、抗凝固薬、抗血小板薬、降圧薬などで治療することができます。

脳卒中管理市場の成長は、脳卒中発症率の上昇、画像診断の技術開拓、脳卒中管理のための遠隔医療導入の急増によって促進されています。

座りがちなライフスタイル、不健康な食生活、高いストレスレベルなどの要因が、脳卒中発症率の上昇につながります。例えば、世界保健機関（WHO）が2022年の世界脳卒中デーに発表したデータによると、脳卒中は全世界で死因の第2位を占めています。同資料によると、脳卒中の生涯発症リスクは50％増加しており、現在、4人に1人が生涯に脳卒中を発症すると推定されています。このような脳卒中発症の増加により、効果的な治療や管理戦略に対する需要が高まり、脳卒中管理市場の成長を牽引しています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 脳卒中発症の増加
  - 脳卒中管理の技術開発
  - 脳卒中に対する意識の大幅な向上
- 抑制要因
  - 脳卒中の診断と治療にかかるコストの高さ
- 機会
  - 人工知能と機械学習が脳卒中管理に革命をもたらす

第4章脳卒中管理市場：タイプ別

概要
診断
治療薬
ソフトウェア

第5章脳卒中管理市場：用途別

概要
虚血性脳卒中
出血性脳卒中

第6章脳卒中管理市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第7章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング（2022年）

第8章企業プロファイル

Abbott Laboratories
B. Braun SE
Boston Scientific Corporation
Bristol-Myers Squibb Company
Cardinal Health
General Electric Company
Medtronic
Siemens AG
JLK
Heuron Co., Ltd.
Deepnoid Co., Ltd.
NeuraSignal, Inc.
Aidoc
Brainomix
METHINKS
Viz.ai, Inc.
iSchemaView, Inc.
Qure.ai
VasSol Inc.
Koninklijke Philips N.V.
Merck & Co. Inc

図表

LIST OF TABLES

TABLE 01. GLOBAL STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 06. STROKE MANAGEMENT MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 08. STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY REGION, 2022-2032 ($MILLION)
TABLE 09. STROKE MANAGEMENT MARKET FOR HAEMORRHAGIC STROKE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. STROKE MANAGEMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 14. U.S. STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 15. U.S. STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 16. CANADA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. CANADA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. MEXICO STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 19. MEXICO STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. EUROPE STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 23. GERMANY STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. GERMANY STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. FRANCE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. FRANCE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. UK STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. UK STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. ITALY STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. ITALY STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. SPAIN STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 32. SPAIN STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. REST OF EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 38. CHINA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. CHINA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. JAPAN STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. JAPAN STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. INDIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. INDIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. AUSTRALIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. AUSTRALIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. SOUTH KOREA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 51. LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. LAMEA STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. BRAZIL STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. BRAZIL STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. REST OF LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 65. B. BRAUN SE: KEY EXECUTIVES
TABLE 66. B. BRAUN SE: COMPANY SNAPSHOT
TABLE 67. B. BRAUN SE: PRODUCT SEGMENTS
TABLE 68. B. BRAUN SE: PRODUCT PORTFOLIO
TABLE 69. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
TABLE 70. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 71. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
TABLE 72. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 73. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 74. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 75. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 76. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 77. CARDINAL HEALTH: KEY EXECUTIVES
TABLE 78. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 79. CARDINAL HEALTH: PRODUCT SEGMENTS
TABLE 80. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 81. GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
TABLE 82. GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
TABLE 83. GENERAL ELECTRIC COMPANY: PRODUCT SEGMENTS
TABLE 84. GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
TABLE 85. GENERAL ELECTRIC COMPANY: KEY STRATERGIES
TABLE 86. MEDTRONIC: KEY EXECUTIVES
TABLE 87. MEDTRONIC: COMPANY SNAPSHOT
TABLE 88. MEDTRONIC: PRODUCT SEGMENTS
TABLE 89. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 90. SIEMENS AG: KEY EXECUTIVES
TABLE 91. SIEMENS AG: COMPANY SNAPSHOT
TABLE 92. SIEMENS AG: PRODUCT SEGMENTS
TABLE 93. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 94. SIEMENS AG: KEY STRATERGIES
TABLE 95. JLK: KEY EXECUTIVES
TABLE 96. JLK: COMPANY SNAPSHOT
TABLE 97. JLK: PRODUCT SEGMENTS
TABLE 98. JLK: PRODUCT PORTFOLIO
TABLE 99. HEURON CO., LTD.: KEY EXECUTIVES
TABLE 100. HEURON CO., LTD.: COMPANY SNAPSHOT
TABLE 101. HEURON CO., LTD.: PRODUCT SEGMENTS
TABLE 102. HEURON CO., LTD.: PRODUCT PORTFOLIO
TABLE 103. HEURON CO., LTD.: KEY STRATERGIES
TABLE 104. DEEPNOID CO., LTD.: KEY EXECUTIVES
TABLE 105. DEEPNOID CO., LTD.: COMPANY SNAPSHOT
TABLE 106. DEEPNOID CO., LTD.: PRODUCT SEGMENTS
TABLE 107. DEEPNOID CO., LTD.: PRODUCT PORTFOLIO
TABLE 108. NEURASIGNAL, INC.: KEY EXECUTIVES
TABLE 109. NEURASIGNAL, INC.: COMPANY SNAPSHOT
TABLE 110. NEURASIGNAL, INC.: PRODUCT SEGMENTS
TABLE 111. NEURASIGNAL, INC.: PRODUCT PORTFOLIO
TABLE 112. NEURASIGNAL, INC.: KEY STRATERGIES
TABLE 113. AIDOC: KEY EXECUTIVES
TABLE 114. AIDOC: COMPANY SNAPSHOT
TABLE 115. AIDOC: PRODUCT SEGMENTS
TABLE 116. AIDOC: PRODUCT PORTFOLIO
TABLE 117. BRAINOMIX: KEY EXECUTIVES
TABLE 118. BRAINOMIX: COMPANY SNAPSHOT
TABLE 119. BRAINOMIX: PRODUCT SEGMENTS
TABLE 120. BRAINOMIX: PRODUCT PORTFOLIO
TABLE 121. BRAINOMIX: KEY STRATERGIES
TABLE 122. METHINKS: KEY EXECUTIVES
TABLE 123. METHINKS: COMPANY SNAPSHOT
TABLE 124. METHINKS: PRODUCT SEGMENTS
TABLE 125. METHINKS: PRODUCT PORTFOLIO
TABLE 126. METHINKS: KEY STRATERGIES
TABLE 127. VIZ.AI, INC.: KEY EXECUTIVES
TABLE 128. VIZ.AI, INC.: COMPANY SNAPSHOT
TABLE 129. VIZ.AI, INC.: PRODUCT SEGMENTS
TABLE 130. VIZ.AI, INC.: PRODUCT PORTFOLIO
TABLE 131. VIZ.AI, INC.: KEY STRATERGIES
TABLE 132. ISCHEMAVIEW, INC.: KEY EXECUTIVES
TABLE 133. ISCHEMAVIEW, INC.: COMPANY SNAPSHOT
TABLE 134. ISCHEMAVIEW, INC.: PRODUCT SEGMENTS
TABLE 135. ISCHEMAVIEW, INC.: PRODUCT PORTFOLIO
TABLE 136. ISCHEMAVIEW, INC.: KEY STRATERGIES
TABLE 137. QURE.AI: KEY EXECUTIVES
TABLE 138. QURE.AI: COMPANY SNAPSHOT
TABLE 139. QURE.AI: PRODUCT SEGMENTS
TABLE 140. QURE.AI: PRODUCT PORTFOLIO
TABLE 141. QURE.AI: KEY STRATERGIES
TABLE 142. VASSOL INC.: KEY EXECUTIVES
TABLE 143. VASSOL INC.: COMPANY SNAPSHOT
TABLE 144. VASSOL INC.: PRODUCT SEGMENTS
TABLE 145. VASSOL INC.: PRODUCT PORTFOLIO
TABLE 146. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 147. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 148. KONINKLIJKE PHILIPS N.V.: SERVICE SEGMENTS
TABLE 149. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 150. MERCK & CO. INC: KEY EXECUTIVES
TABLE 151. MERCK & CO. INC: COMPANY SNAPSHOT
TABLE 152. MERCK & CO. INC: PRODUCT SEGMENTS
TABLE 153. MERCK & CO. INC: PRODUCT PORTFOLIO
TABLE 154. MERCK & CO. INC: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. STROKE MANAGEMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF STROKE MANAGEMENT MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN STROKE MANAGEMENT MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN STROKE MANAGEMENT MARKET (2022-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL STROKE MANAGEMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. STROKE MANAGEMENT MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. STROKE MANAGEMENT MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR HAEMORRHAGIC STROKE, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. STROKE MANAGEMENT MARKET BY REGION, 2022 AND 2032(%)
FIGURE 19. U.S. STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 20. CANADA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 21. MEXICO STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 22. GERMANY STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 23. FRANCE STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 24. UK STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 25. ITALY STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 26. SPAIN STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 27. REST OF EUROPE STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 28. CHINA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 29. JAPAN STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 30. INDIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 31. AUSTRALIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 32. SOUTH KOREA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 33. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 34. BRAZIL STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 35. SAUDI ARABIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH AFRICA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF LAMEA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
FIGURE 38. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 42. COMPETITIVE DASHBOARD
FIGURE 43. COMPETITIVE HEATMAP: STROKE MANAGEMENT MARKET
FIGURE 44. TOP PLAYER POSITIONING, 2022
FIGURE 45. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 48. B. BRAUN SE: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 49. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. B. BRAUN SE: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 53. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. CARDINAL HEALTH: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. CARDINAL HEALTH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. GENERAL ELECTRIC COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 60. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. MEDTRONIC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. MEDTRONIC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. SIEMENS AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 67. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 69. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
FIGURE 70. KONINKLIJKE PHILIPS N.V.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 71. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 72. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. MERCK & CO. INC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 74. MERCK & CO. INC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 75. MERCK & CO. INC: REVENUE SHARE BY REGION, 2021 (%)

Product Code: A00539

According to a new report published by Allied Market Research, titled, "Stroke Management Market," The stroke management market was valued at $36.1 billion in 2022, and is estimated to reach $74 billion by 2032, growing at a CAGR of 7.4% from 2022 to 2032.

A stroke is a medical condition that occurs when the blood supply to the brain is abruptly cut off due to rupturing of blood vessels or blockage in blood supply to brain. This leads to depletion of oxygen to brain tissues, which results in the rapid death of brain cells. There are mainly three types of strokes namely ischemic stroke, transient ischemic attack, and hemorrhagic stroke. A comprehensive approach to the diagnosis and treatment of people who suffered from stroke is called stroke management. The diagnosis of stroke includes magnetic resonance imaging, carotid ultrasound, cerebral angiography, blood tests, and others. Stoke can be treated with tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive medicines.

The stroke management market growth is driven by rising incidence of stroke, technological development in diagnostic imaging, and surge in adoption of telemedicine for stroke management. Factors such as

1) sedentary lifestyle, unhealthy diets, and high stress levels leads to rise in incidences of stroke. For instance, according to the data published by World Health Organization (WHO), on World Stroke Day 2022, reported that stroke is the second leading cause of death across the globe. As per the same source, the lifetime risk of developing a stroke has increased by 50% and currently 1 in 4 people is estimated to have a stroke in their lifetime. This rise in stroke incidences has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the stroke management market.

In addition, the technological advancement in the diagnostic techniques also drives the market growth. The advanced imaging technologies such as

1) magnetic resonance imaging and angiography systems have improved the diagnosis of stroke and enhanced patient care. For instance, Siemens Healthineers, a global medical technology company has received the Food and Drug Administration (FDA) approval for its ARTIS icono ceiling. ARTIS icono ceiling is an angiography system used for the advanced procedures in the interventional cardiology. Thus, technological advancement in the stroke imaging techniques further boost the market growth.

However, the high cost of stroke diagnosis and treatment limit the growth of stroke management market. The economic burden of stroke is the major factor hampering the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the growth of stroke management market.

On the other hand, surge in adoption of artificial intelligence for stroke management, increase in awareness about preventive healthcare, and rise in geriatric population in developing countries are expected to create lucrative opportunities for market growth during the forecast period.

The stroke management market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into diagnostics, therapeutics, and software. The diagnostic segment is further categorized into magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The therapeutics segment is further divided into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. As per application, the market is bifurcated into ischemic stroke and hemorrhagic stroke.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global stroke management market are Abbott Laboratories, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, General Electric Company, Medtronic, Siemens AG, Aidoc, Brainomix, VasSol Inc., Qure.ai, Viz.ai, Inc., METHINKS, B Braun SE, iSchemaView, Inc., NeuraSignal, Inc., Deepnoid Co., Ltd., Heuron Co., Ltd., JLK, Koninklijke Philips N.V., and Merck & Co. Inc. Key players operating in the market have adopted product approval, acquisition, partnership, and product launch as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stroke management market analysis from 2022 to 2032 to identify the prevailing stroke management market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the stroke management market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global stroke management market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Diagnostics
- Type
- Magnetic Resonance Imaging
- Carotid Ultrasound
- Cerebral Angiography
- Electrocardiography
- Echocardiography
- Others
Therapeutics
- Type
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
Software

By Application

Ischemic Stroke
Haemorrhagic Stroke

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Boston Scientific Corporation
Bristol-Myers Squibb Company
General Electric Company
Medtronic
Aidoc
Brainomix
Qure.ai
METHINKS
iSchemaView, Inc.
Deepnoid Co., Ltd.
Heuron Co., Ltd.
B. Braun SE
Koninklijke Philips N.V.
Abbott Laboratories
Cardinal Health
Siemens AG
VasSol Inc.
Viz.ai, Inc.
NeuraSignal, Inc.
JLK
Merck & Co. Inc

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in the incidences of stroke
  - 3.4.1.2. Technological development in stroke management
  - 3.4.1.3. Significant increase in stroke awareness
- 3.4.2. Restraints
  - 3.4.2.1. High cost of stroke diagnostics and treatment
- 3.4.3. Opportunities
  - 3.4.3.1. Artificial intelligence and machine learning are revolutionizing stroke management

CHAPTER 4: STROKE MANAGEMENT MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Diagnostics
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Diagnostics Stroke Management Market by Type
4.3. Therapeutics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Therapeutics Stroke Management Market by Type
4.4. Software
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: STROKE MANAGEMENT MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Ischemic Stroke
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Haemorrhagic Stroke
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: STROKE MANAGEMENT MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Type
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Type
  - 6.2.4.1.2. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Type
  - 6.2.4.2.2. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Type
  - 6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Type
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Type
  - 6.3.4.1.2. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Type
  - 6.3.4.2.2. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Type
  - 6.3.4.3.2. Market size and forecast, by Application
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Type
  - 6.3.4.4.2. Market size and forecast, by Application
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Type
  - 6.3.4.5.2. Market size and forecast, by Application
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Type
  - 6.3.4.6.2. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Type
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. China
  - 6.4.4.1.1. Market size and forecast, by Type
  - 6.4.4.1.2. Market size and forecast, by Application
  - 6.4.4.2. Japan
  - 6.4.4.2.1. Market size and forecast, by Type
  - 6.4.4.2.2. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Market size and forecast, by Type
  - 6.4.4.3.2. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Market size and forecast, by Type
  - 6.4.4.4.2. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Type
  - 6.4.4.5.2. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Type
  - 6.4.4.6.2. Market size and forecast, by Application
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Type
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Type
  - 6.5.4.1.2. Market size and forecast, by Application
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Market size and forecast, by Type
  - 6.5.4.2.2. Market size and forecast, by Application
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Market size and forecast, by Type
  - 6.5.4.3.2. Market size and forecast, by Application
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Market size and forecast, by Type
  - 6.5.4.4.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Abbott Laboratories
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. B. Braun SE
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Boston Scientific Corporation
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Bristol-Myers Squibb Company
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Cardinal Health
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
8.6. General Electric Company
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. Medtronic
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Siemens AG
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
8.9. JLK
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
8.10. Heuron Co., Ltd.
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Key strategic moves and developments
8.11. Deepnoid Co., Ltd.
- 8.11.1. Company overview
- 8.11.2. Key executives
- 8.11.3. Company snapshot
- 8.11.4. Operating business segments
- 8.11.5. Product portfolio
8.12. NeuraSignal, Inc.
- 8.12.1. Company overview
- 8.12.2. Key executives
- 8.12.3. Company snapshot
- 8.12.4. Operating business segments
- 8.12.5. Product portfolio
- 8.12.6. Key strategic moves and developments
8.13. Aidoc
- 8.13.1. Company overview
- 8.13.2. Key executives
- 8.13.3. Company snapshot
- 8.13.4. Operating business segments
- 8.13.5. Product portfolio
8.14. Brainomix
- 8.14.1. Company overview
- 8.14.2. Key executives
- 8.14.3. Company snapshot
- 8.14.4. Operating business segments
- 8.14.5. Product portfolio
- 8.14.6. Key strategic moves and developments
8.15. METHINKS
- 8.15.1. Company overview
- 8.15.2. Key executives
- 8.15.3. Company snapshot
- 8.15.4. Operating business segments
- 8.15.5. Product portfolio
- 8.15.6. Key strategic moves and developments
8.16. Viz.ai, Inc.
- 8.16.1. Company overview
- 8.16.2. Key executives
- 8.16.3. Company snapshot
- 8.16.4. Operating business segments
- 8.16.5. Product portfolio
- 8.16.6. Key strategic moves and developments
8.17. iSchemaView, Inc.
- 8.17.1. Company overview
- 8.17.2. Key executives
- 8.17.3. Company snapshot
- 8.17.4. Operating business segments
- 8.17.5. Product portfolio
- 8.17.6. Key strategic moves and developments
8.18. Qure.ai
- 8.18.1. Company overview
- 8.18.2. Key executives
- 8.18.3. Company snapshot
- 8.18.4. Operating business segments
- 8.18.5. Product portfolio
- 8.18.6. Key strategic moves and developments
8.19. VasSol Inc.
- 8.19.1. Company overview
- 8.19.2. Key executives
- 8.19.3. Company snapshot
- 8.19.4. Operating business segments
- 8.19.5. Product portfolio
8.20. Koninklijke Philips N.V.
- 8.20.1. Company overview
- 8.20.2. Key executives
- 8.20.3. Company snapshot
- 8.20.4. Operating business segments
- 8.20.5. Product portfolio
- 8.20.6. Business performance
8.21. Merck & Co. Inc
- 8.21.1. Company overview
- 8.21.2. Key executives
- 8.21.3. Company snapshot
- 8.21.4. Operating business segments
- 8.21.5. Product portfolio
- 8.21.6. Business performance
- 8.21.7. Key strategic moves and developments

脳卒中管理の世界市場：タイプ別、用途別：機会分析と産業予測（2022年～2032年）

Stroke Management Market By Type (Diagnostics, Therapeutics, Software), By Application (Ischemic Stroke, Haemorrhagic Stroke): Global Opportunity Analysis and Industry Forecast, 2022-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章脳卒中管理市場：タイプ別

第5章脳卒中管理市場：用途別

第6章脳卒中管理市場：地域別

第7章競合情勢

第8章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: STROKE MANAGEMENT MARKET, BY TYPE

CHAPTER 5: STROKE MANAGEMENT MARKET, BY APPLICATION

CHAPTER 6: STROKE MANAGEMENT MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

脳卒中管理の世界市場：タイプ別、用途別：機会分析と産業予測（2022年～2032年）

Stroke Management Market By Type (Diagnostics, Therapeutics, Software), By Application (Ischemic Stroke, Haemorrhagic Stroke): Global Opportunity Analysis and Industry Forecast, 2022-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 脳卒中管理市場：タイプ別

第5章 脳卒中管理市場：用途別

第6章 脳卒中管理市場：地域別

第7章 競合情勢

第8章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: STROKE MANAGEMENT MARKET, BY TYPE

CHAPTER 5: STROKE MANAGEMENT MARKET, BY APPLICATION

CHAPTER 6: STROKE MANAGEMENT MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章脳卒中管理市場：タイプ別

第5章脳卒中管理市場：用途別

第6章脳卒中管理市場：地域別

第7章競合情勢

第8章企業プロファイル